FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
-- Raises 2015 revenue and gross margin guidance to reflect recent licensing transaction with Merck --
-- Conference call begins at 4:30 p.m. Eastern time today --
REDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the three and six months ended June 30, 2015, and raises its revenue and gross margin outlook for 2015.
"Solid year-to-date progress executing our plans encourages us to raise both of our annual... More
-- Raises 2015 revenue and gross margin guidance to reflect recent licensing transaction with Merck --
-- Conference call begins at 4:30 p.m. Eastern time today --
REDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the three and six months ended June 30, 2015, and raises its revenue and gross margin outlook for 2015.
"Solid year-to-date progress executing our plans encourages us to raise both of our annual... More
REDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, today announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolver® protein engineering platform technology with a company in the biopharmaceutical industry.
Under the terms of the agreement, Codexis will employ CodeEvolver to develop a novel enzyme for use in its partner's preclinical therapeutic development program. Development of the new enzyme will occur in... More
REDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, today announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolver® protein engineering platform technology with a company in the biopharmaceutical industry.
Under the terms of the agreement, Codexis will employ CodeEvolver to develop a novel enzyme for use in its partner's preclinical therapeutic development program. Development of the new enzyme will occur in... More
